Verifying Perpetrator Single-Drug Pharmacokinetics

Why Verify the Perpetrator Before Modeling Its CYP Effect?

A perpetrator PBPK model supplies concentrations that may be used to drive inhibition, inactivation, or induction. If the model misses the perpetrator’s measured concentration-time course, it can also misrepresent the magnitude or timing of CYP modulation. A plausible interaction prediction is not a substitute for checking the perpetrator’s own pharmacokinetics under the dose, route, and regimen intended for the interaction simulation.

This check concerns the perpetrator as a single drug: does the model reproduce its observed exposure profile, AUC, peak concentration, and, when repeated-dose data are available, accumulation? It does not establish that the enzyme-effect parameters are correct. It establishes whether the concentration input to those mechanisms is credible for the conditions examined.

Set Up a Like-for-Like Comparison

Before calculating metrics, confirm that the model and data represent the same drug product, dose, route, dosing interval, fed or fasted condition, and population context. Check whether concentrations refer to parent drug or a metabolite, and whether the reported matrix is plasma, serum, or whole blood. A mismatch in any of these can look like a model error even when the comparison is not actually like-for-like.

For concentration \(C(t)\), the area under the concentration-time curve over an interval from \(t_1\) to \(t_2\) is \(\mathrm{AUC}_{t_1-t_2}=\int_{t_1}^{t_2}C(t)\,dt\). The maximum concentration over a specified profile is \(C_{\max}=\max_t C(t)\); the associated time is \(T_{\max}\). AUC has units of concentration multiplied by time, while \(C_{\max}\) has units of concentration. The interval must be stated: for example, single-dose AUC from zero to the last measurable time is not automatically interchangeable with steady-state \(\mathrm{AUC}_{\tau}\).

When observations are available only at discrete times, a common approximation is the linear trapezoidal rule. For adjacent measurements \(C_i\) and \(C_{i+1}\), separated by \(\Delta t_i=t_{i+1}-t_i\), the interval contribution is \((C_i+C_{i+1})\Delta t_i/2\). Summing these contributions gives an estimated AUC over the sampled interval. This approximation does not recover unobserved portions of the profile; extrapolation beyond the last sample requires an explicit method and suitable terminal-phase data.

Accumulation Across Repeated Doses

For a repeated regimen, define the accumulation ratio by comparing a steady-state summary with the corresponding summary after the first dose. One possible AUC ratio is \(\mathrm{AUC}_{\tau,\mathrm{ss}}/\mathrm{AUC}_{0-\tau,\mathrm{first}}\); a peak ratio is \(C_{\max,\mathrm{ss}}/C_{\max,\mathrm{first}}\). State which ratio is used and the time windows. These ratios need not be equal, particularly when absorption is prolonged or the profile shape changes over the interval.

The comparison assumes the dose and interval are unchanged and that PK is linear and time-invariant: each dose produces the same concentration response, concentrations add by superposition, and clearance and bioavailability do not change over time. Under these conditions, accumulation reflects residual drug from earlier doses. Nonlinear PK, time-varying clearance, autoinduction, time-dependent inhibition of the perpetrator’s own elimination, or changing adherence can invalidate a simple interpretation.

A useful special case is a one-compartment model with instantaneous input and first-order elimination, with elimination rate constant \(k\) and dosing interval \(\tau\). After one dose, concentration declines in proportion to \(e^{-kt}\). At steady state, the post-dose peak is the sum of the current dose’s contribution and the residual contributions from all earlier doses:

The last equality follows from the convergent geometric series, which requires \(0<e^{-k\tau}<1\), or equivalently \(k>0\) and \(\tau>0\). In this special model, the same ratio applies to the AUC over one interval at steady state relative to the first-dose AUC over that interval. It is not a universal formula for oral dosing with absorption, multicompartment disposition, or nonlinear PK; in those cases, calculate the ratios from the appropriate model profiles.

Justifying the Steady-State AUC Relationship

A broader result applies to stable linear time-invariant PK, even when the concentration-time response to one dose is not a single exponential. Let \(c_1(t)\) be the concentration response to one dose, with \(c_1(t)=0\) for \(t<0\), and suppose its total AUC is finite. At periodic steady state, within an interval \(0\leq t<\tau\), the concentration is the sum of the current dose response and residual responses from earlier doses:

Integrating over one dosing interval and changing variables in each term gives

The result says that steady-state AUC over an interval equals the total AUC after a single dose under these assumptions. It does not say that \(\mathrm{AUC}_{\tau,\mathrm{ss}}\) equals the first-dose AUC truncated at \(\tau\). Nor does it provide an accumulation ratio without specifying the denominator. This distinction matters when a single-dose profile is sampled only through one dosing interval.

Worked Assessment of a Repeated-Dose Mismatch

Diagnostics, Alternatives, and Limitations

A reliable assessment uses summaries and the full profile together. AUC is informative about integrated exposure, but it can agree despite a mistimed or misshaped profile. \(C_{\max}\) and \(T_{\max}\) help expose peak magnitude and timing errors, while trough concentrations can reveal an incorrect decline or accumulation pattern. Plot observed and predicted concentrations on both linear and logarithmic scales when feasible; the latter can make terminal-phase mismatches easier to see. Examine signed residuals, \(C_{\mathrm{pred}}-C_{\mathrm{obs}}\), by time rather than relying only on an overall average error.

If the model is systematically low early and high late, or vice versa, investigate absorption rate, lag time, distribution, and sampling alignment before changing clearance to fix AUC. If all concentrations are proportionally high or low, check dose, bioavailability, clearance, and units. If single-dose exposure is acceptable but repeated-dose accumulation is not, check the dosing interval, elimination behavior, time dependence, and whether the observations represent the intended steady state. These are diagnostic directions, not unique explanations: multiple parameter combinations can produce similar summaries.

AUC and \(C_{\max}\) comparisons are complementary to pointwise profile checks, not replacements for them. A fitted model may reproduce the data used for parameter estimation yet perform poorly in an independent regimen. Conversely, a small pointwise discrepancy at a sparsely sampled peak may be difficult to interpret. Assess uncertainty and the study’s sampling design; do not treat each sampled concentration as error-free or assume an apparent small discrepancy proves model validity. Finally, perpetrator single-drug verification does not verify the victim’s baseline PK, the CYP effect model, or the predicted DDI magnitude.

Common Pitfall